LabGenius' CTO, Leonard Wossnig, discusses the intersection of synthetic biology, high-throughput assays, and machine learning in the quest for cancer drugs with Harry Glorikian
BBC News covers LabGenius and how it harnesses AI in the search for new medicines
LabGenius' CEO, James Field, discusses ML-enabled drug discovery with Patrick Short on the Genetics Podcast
PwC | The Life Sciences Future50
The Bio Report | Leveraging Generative AI to Design Therapeutic Antibodies
SynBioBeta | Machine Learning Enhances Antibody Discovery: A Glimpse into LabGenius and Sanofi's Collaborative Endeavour
TechCrunch | Questions Every VC Needs to Ask About Every AI Startup’s Tech Stack
WIRED Feature | AI is Building Highly Effective Antibodies That Humans Can’t Even Imagine
LabGenius' CEO, James Field, discusses ML-enabled drug discovery as a recent guest on the Business of Biotech podcast
LabGenius featured in the inaugural edition of the Decoding Bio Snapshot
LabGenius' CEO & founder appeared live on Bloomberg News to talk about the drug discovery revolution that's taking place at the interface of biology and technology
Catch the latest results from LabGenius' ML-driven T-cell engager optimisation capability in Labiotech.eu
Emily Brady from Obvious Ventures highlights LabGenius' big bold mission to accelerate the AI search for protein therapeutics.
Founder & CEO, James Field, explains how LabGenius is combining human and machine intelligence to accelerate research into advanced medicines
Founder and CEO, James Field, took part in the BIOS Community Spotlight Series
Convolutional neural networks help design better protein therapeutics
LabGenius recognized by Sifted as a London startup to watch
LabGenius closes $15 million Series A extension led by Atomico, brings round to $25 million
This startup is using robots and A.I. to design new drugs
Active machine learning helps drug hunters tackle biology
